bladder cancer cell line ej cl-0274 Search Results


bladder cancer cell line ej cl-0274  (Procell Inc)
90
Procell Inc bladder cancer cell line ej cl-0274
LASP2 expression is decreased in patients with <t>bladder</t> <t>cancer.</t> (A) LASP2 mRNA expression in 60 pairs of bladder cancer and adjacent non-tumor tissues. (B) LASP2 mRNA expression in NUCs and bladder cancer <t>cell</t> lines (EJ, 5637, UM-UC-3, T24 and TCCSUP). *P<0.05 vs NUC. (C) Kaplan-Meier analysis of overall and recurrent-free survival rates stratified by low and high LASP2 expression (n=98/group). LASP2, LIM and SH3 Protein 2; NUC, normal urothelial cell; T/N, tumor/normal.
Bladder Cancer Cell Line Ej Cl 0274, supplied by Procell Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/bladder cancer cell line ej cl-0274/product/Procell Inc
Average 90 stars, based on 1 article reviews
bladder cancer cell line ej cl-0274 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


LASP2 expression is decreased in patients with bladder cancer. (A) LASP2 mRNA expression in 60 pairs of bladder cancer and adjacent non-tumor tissues. (B) LASP2 mRNA expression in NUCs and bladder cancer cell lines (EJ, 5637, UM-UC-3, T24 and TCCSUP). *P<0.05 vs NUC. (C) Kaplan-Meier analysis of overall and recurrent-free survival rates stratified by low and high LASP2 expression (n=98/group). LASP2, LIM and SH3 Protein 2; NUC, normal urothelial cell; T/N, tumor/normal.

Journal: Experimental and Therapeutic Medicine

Article Title: LASP2 suppressed malignancy and Wnt/β-catenin signaling pathway activation in bladder cancer

doi: 10.3892/etm.2018.6836

Figure Lengend Snippet: LASP2 expression is decreased in patients with bladder cancer. (A) LASP2 mRNA expression in 60 pairs of bladder cancer and adjacent non-tumor tissues. (B) LASP2 mRNA expression in NUCs and bladder cancer cell lines (EJ, 5637, UM-UC-3, T24 and TCCSUP). *P<0.05 vs NUC. (C) Kaplan-Meier analysis of overall and recurrent-free survival rates stratified by low and high LASP2 expression (n=98/group). LASP2, LIM and SH3 Protein 2; NUC, normal urothelial cell; T/N, tumor/normal.

Article Snippet: The bladder cancer cell line EJ (cat. no. CL-0274) was obtained from Procell Life Science and Technology Co., Ltd. (Wuhan, China), and 5637 (cat. no. TCHu 1), UM-UC-3 (cat. no. TCHu 217), T24 (cat. no. SCSP-536) and TCCSUP (cat. no. SCSP-571) bladder cancer cell lines were obtained from the Cell Bank of Chinese Academy of Sciences (Shanghai, China).

Techniques: Expressing

LASP2 upregulation inhibits bladder cancer cell aggressiveness. (A) Western blotting analysis of LASP2 expression in EJ and T24 cells. (B) Representative images (left panel, ×200) and quantification (right panel) of EdU incorporation in EJ and T24 bladder cancer cells. DAPI was used as a DNA stain. Representative images (left panel) and quantification (right panel) of (C) HUVECs cultured on Matrigel-coated plates with conditioned medium from LASP2-overexpressing cells, (magnification, ×200) (D) migratory cells assessed using a wound healing assay and (E) migratory cells assessed using Transwell migration and Matrigel invasion assays, respectively (magnification, ×200). *P<0.05. EdU, 5-ethynyl-2′-deoxyuridine; HUVEC, human umbilical vein endothelial cell; LASP2, LIM and SH3 Protein 2.

Journal: Experimental and Therapeutic Medicine

Article Title: LASP2 suppressed malignancy and Wnt/β-catenin signaling pathway activation in bladder cancer

doi: 10.3892/etm.2018.6836

Figure Lengend Snippet: LASP2 upregulation inhibits bladder cancer cell aggressiveness. (A) Western blotting analysis of LASP2 expression in EJ and T24 cells. (B) Representative images (left panel, ×200) and quantification (right panel) of EdU incorporation in EJ and T24 bladder cancer cells. DAPI was used as a DNA stain. Representative images (left panel) and quantification (right panel) of (C) HUVECs cultured on Matrigel-coated plates with conditioned medium from LASP2-overexpressing cells, (magnification, ×200) (D) migratory cells assessed using a wound healing assay and (E) migratory cells assessed using Transwell migration and Matrigel invasion assays, respectively (magnification, ×200). *P<0.05. EdU, 5-ethynyl-2′-deoxyuridine; HUVEC, human umbilical vein endothelial cell; LASP2, LIM and SH3 Protein 2.

Article Snippet: The bladder cancer cell line EJ (cat. no. CL-0274) was obtained from Procell Life Science and Technology Co., Ltd. (Wuhan, China), and 5637 (cat. no. TCHu 1), UM-UC-3 (cat. no. TCHu 217), T24 (cat. no. SCSP-536) and TCCSUP (cat. no. SCSP-571) bladder cancer cell lines were obtained from the Cell Bank of Chinese Academy of Sciences (Shanghai, China).

Techniques: Western Blot, Expressing, Staining, Cell Culture, Wound Healing Assay, Migration

LASP2 downregulation promotes bladder cancer cell aggressiveness. (A) Western blotting analysis of LASP2 expression in LASP2 knockdown EJ and T24 cells. (B) Representative images (left panel) and quantification (right panel) of EdU incorporation in EJ and T24 bladder cancer cells. DAPI was used as a DNA stain. Representative images (left panel) and quantification (right panel) of (C) HUVECs cultured on Matrigel-coated plates with conditioned medium from LASP2-silenced cells, (D) migratory cells assessed using a wound healing assay and (E) migratory cells assessed using transwell migration and Matrigel invasion assays, respectively. *P<0.05. EdU, 5-ethynyl-2′-deoxyuridine; HUVEC, human umbilical vein endothelial cell; LASP2, LIM and SH3 Protein 2; Ri, RNA interference.

Journal: Experimental and Therapeutic Medicine

Article Title: LASP2 suppressed malignancy and Wnt/β-catenin signaling pathway activation in bladder cancer

doi: 10.3892/etm.2018.6836

Figure Lengend Snippet: LASP2 downregulation promotes bladder cancer cell aggressiveness. (A) Western blotting analysis of LASP2 expression in LASP2 knockdown EJ and T24 cells. (B) Representative images (left panel) and quantification (right panel) of EdU incorporation in EJ and T24 bladder cancer cells. DAPI was used as a DNA stain. Representative images (left panel) and quantification (right panel) of (C) HUVECs cultured on Matrigel-coated plates with conditioned medium from LASP2-silenced cells, (D) migratory cells assessed using a wound healing assay and (E) migratory cells assessed using transwell migration and Matrigel invasion assays, respectively. *P<0.05. EdU, 5-ethynyl-2′-deoxyuridine; HUVEC, human umbilical vein endothelial cell; LASP2, LIM and SH3 Protein 2; Ri, RNA interference.

Article Snippet: The bladder cancer cell line EJ (cat. no. CL-0274) was obtained from Procell Life Science and Technology Co., Ltd. (Wuhan, China), and 5637 (cat. no. TCHu 1), UM-UC-3 (cat. no. TCHu 217), T24 (cat. no. SCSP-536) and TCCSUP (cat. no. SCSP-571) bladder cancer cell lines were obtained from the Cell Bank of Chinese Academy of Sciences (Shanghai, China).

Techniques: Western Blot, Expressing, Knockdown, Staining, Cell Culture, Wound Healing Assay, Migration

LASP2 is associated with proteins in the Wnt/ β -catenin signaling pathway in bladder cancer cells. Western blotting results of LASP2, cyclin D1 and nuclear β -catenin expression in six samples from patients with bladder cancer. Nuclear matrix protein P84 was used as a loading control. LASP2, LIM and SH3 Protein 2.

Journal: Experimental and Therapeutic Medicine

Article Title: LASP2 suppressed malignancy and Wnt/β-catenin signaling pathway activation in bladder cancer

doi: 10.3892/etm.2018.6836

Figure Lengend Snippet: LASP2 is associated with proteins in the Wnt/ β -catenin signaling pathway in bladder cancer cells. Western blotting results of LASP2, cyclin D1 and nuclear β -catenin expression in six samples from patients with bladder cancer. Nuclear matrix protein P84 was used as a loading control. LASP2, LIM and SH3 Protein 2.

Article Snippet: The bladder cancer cell line EJ (cat. no. CL-0274) was obtained from Procell Life Science and Technology Co., Ltd. (Wuhan, China), and 5637 (cat. no. TCHu 1), UM-UC-3 (cat. no. TCHu 217), T24 (cat. no. SCSP-536) and TCCSUP (cat. no. SCSP-571) bladder cancer cell lines were obtained from the Cell Bank of Chinese Academy of Sciences (Shanghai, China).

Techniques: Western Blot, Expressing, Control